Effectiveness and safety of macrolides in bronchiectasis patients: a meta-analysis and systematic review.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Pulmonary Pharmacology & Therapeutics

• Publication date

  2014-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.pupt.2013.09.003PMID 24076368
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Macrolides for diffuse panbronchiolitis.

  2015cited by this paper
• Macrolides for diffuse panbronchiolitis.

  2013cited by this paper
• Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial.

  2013cited by this paper
• Effects of long‐term azithromycin therapy on airway oxidative stress markers in non‐cystic fibrosis bronchiectasis

  2013cited by this paper
• Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial.

  2013influential reference
• Macrolide antibiotics for cystic fibrosis.

  2012cited by this paper
• Azithromycin and the risk of cardiovascular death.

  2012cited by this paper
• Macrolide antibiotics for cystic fibrosis.

  2012cited by this paper
• Azithromycin for Indigenous children with bronchiectasis: study protocol for a multi-centre randomized controlled trial

  2012cited by this paper
• Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial.

  2012cited by this paper
• Effect of Azithromycin on Pulmonary Function in Patients With Cystic Fibrosis Uninfected With Pseudomonas aeruginosa: A Randomized Controlled Trial

  2012cited by this paper
• Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis

  2012influential reference
• Azithromycin and the risk of cardiovascular death.

  2012cited by this paper
• Bronchiectasis--diagnosis and treatment.

  2011cited by this paper
• Long-term, low-dose erythromycin in bronchiectasis subjects with frequent infective exacerbations.

  2011cited by this paper
• Stationary biofilm growth normalizes mutation frequencies and mutant prevention concentrations in Pseudomonas aeruginosa from cystic fibrosis patients.

  2011cited by this paper
• Azithromycin for prevention of exacerbations of COPD.

  2011cited by this paper
• Effectiveness and safety of macrolides in cystic fibrosis patients: a meta-analysis and systematic review.

  2011cited by this paper
• Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection.

  2011cited by this paper
• Azithromycin for prevention of exacerbations of COPD.

  2011cited by this paper
• Exploratory Study of the Prevalence and Clinical Significance of Tobramycin-Mediated Biofilm Induction in Pseudomonas aeruginosa Isolates from Cystic Fibrosis Patients

  2010cited by this paper
• Efficacy of the Combination of Tobramycin and a Macrolide in an InVitroPseudomonas aeruginosa Mature Biofilm Model

  2010cited by this paper
• Trends in bronchiectasis mortality in England and Wales.

  2010cited by this paper
• Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.

  2010cited by this paper
• Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews

  2009cited by this paper
• Annual macrolide prescription rates and the emergence of macrolide resistance among Streptococcus pneumoniae in Canada from 1995 to 2005.

  2009cited by this paper
• Mortality in bronchiectasis: a long-term study assessing the factors influencing survival

  2009cited by this paper
• Airway inflammation in cystic fibrosis.

  2008cited by this paper
• Macrolide antibiotics as immunomodulatory medications: proposed mechanisms of action.

  2008cited by this paper
• Mucosal inflammation in idiopathic bronchiectasis: cellular and molecular mechanisms

  2008cited by this paper
• Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health.

  2007cited by this paper
• Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis.

  2007cited by this paper
• Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial

  2006cited by this paper
• Community Prescribing and Resistant Streptococcus pneumoniae

  2005cited by this paper
• The Disease-Modifying Effects of Twice-Weekly Oral Azithromycin in Patients with Bronchiectasis

  2005influential reference
• Implications of antimicrobial resistance in the empirical treatment of community-acquired respiratory tract infections: the case of macrolides.

  2002cited by this paper
• Quantifying heterogeneity in a meta‐analysis

  2002cited by this paper
• High proportion of pharyngeal carriers of commensal streptococci resistant to erythromycin in Spanish adults.

  2001cited by this paper
• Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature.

  2000cited by this paper
• A pilot study of low-dose erythromycin in bronchiectasis.

  1999influential reference
• Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double-blind, placebo-controlled study.

  1997cited by this paper
• Validation of the St. George's Respiratory Questionnaire in bronchiectasis.

  1997cited by this paper
• Assessing the quality of reports of randomized clinical trials: is blinding necessary?

  1996cited by this paper
• Meta-analysis, decision analysis, and cost-effectiveness analysis. Methods for quantitative synthesis in medicine

  1995cited by this paper

• Management erwachsener Patientinnen und Patienten mit Bronchiektasen-Erkrankung

  2024cites this paper
• Efficacy and safety of long-term macrolide therapy for non-cystic fibrosis bronchiectasis: A systematic review and meta-analysis.

  2024cites this paper
• Safety profiles and adverse reactions of azithromycin in the treatment of pediatric respiratory diseases: A systematic review and meta-analysis

  2023cites this paper
• Les bronchectasies dans la polyarthrite rhumatoïde : évaluation clinique

  2020cites this paper
• Pulmonary Anti-Inflammatory Effects of Macrolides

  2020cites this paper
• Bronchiectasis in rheumatoid arthritis. A clinical appraisial.

  2020cites this paper
• Duration of Antibiotic Therapy in Non-cystic Fibrosis Bronchiectasis

  2019cites this paper
• Aetiology and disease severity are among the determinants of quality of life in bronchiectasis

  2019cites this paper
• Brazilian consensus on non-cystic fibrosis bronchiectasis

  2019cites this paper
• Current and future pharmacotherapy options for non-cystic fibrosis bronchiectasis

  2018cites this paper
• British Thoracic Society Guideline for bronchiectasis in adults

  2018cites this paper
• Management of airway mucus hypersecretion in chronic airway inflammatory disease: Chinese expert consensus (English edition)

  2018cites this paper
• Survey about the use of clarithromycin in an ENT outpatient department of a tertiary hospital

  2017cites this paper
• Raising awareness of bronchiectasis in primary care: overview of diagnosis and management strategies in adults

  2017cites this paper
• European Respiratory Society guidelines for the management of adult bronchiectasis

  2017cites this paper
• The Saudi Thoracic Society guidelines for diagnosis and management of noncystic fibrosis bronchiectasis

  2017cites this paper
• Macrolide Hybrid Compounds: Drug Discovery Opportunities in Anti- Infective and Anti-inflammatory Area.

  2017cites this paper
• University of Dundee European Respiratory Society guidelines for the management of adult bronchiectasis Polverino,

  2017cites this paper
• Systemic and topical antibiotics for chronic rhinosinusitis.

  2016cites this paper
• Bronchiectasis: What We Don't Know Yet But Should

  2016cites this paper
• Long-term antibiotic treatment for non-cystic fibrosis bronchiectasis in adults: evidence, current practice and future use

  2016cites this paper
• Oral Antibiotics as Anti-infectives

  2015cites this paper
• Effects of long-term use of macrolides in patients with non-cystic fibrosis bronchiectasis: a meta-analysis of randomized controlled trials

  2015cites this paper
• Update in Bronchiectasis 2014.

  2015cites this paper
• Adverse events in people taking macrolide antibiotics versus placebo for any indication.

  2015cites this paper
• Reply to "Letter to the Editor" by Serisier regarding "effectiveness and safety of macrolides in bronchiectasis patients: a meta-analysis and systematic review".

  2014cites this paper
• The role of macrolides in asthma: current evidence and future directions.

  2014cites this paper
• Macrolide treatment in patients with bronchiectasis: more attention should be paid to the number of exacerbations.

  2014cites this paper
• Letter to the editor: inaccurate data in meta-analysis of macrolides by Shi et al.

  2014cites this paper
• Oral targeted therapies in the treatment of pulmonary arterial hypertension: a meta-analysis of clinical trials.

  2014cites this paper